Search

everythinglearnresearchcommunity

for

Search:↓

Finasteride boosts immune cells that suppress T-cells, possibly helping with immune disorders but may increase cancer risk.

Adalimumab helped control a child's severe eye disease when other treatments failed.

SH-340 may improve skin barrier and help treat atopic dermatitis.

Telitacicept effectively improved hair regrowth in a woman with lupus and alopecia.

Topical squaric acid dibutylester worsened discoid lupus erythematosus in a patient.

Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.

Erenumab significantly reduced migraine days or severity in most patients after 3 months.

Baricitinib can help improve hair loss and skin color issues in people with Down syndrome.

Dutasteride more effectively lowers DHT levels in men with enlarged prostates than finasteride.

Combining delgocitinib ointment with excimer laser can effectively treat severe alopecia areata.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

IL-17C is important in inflammatory skin diseases and could be a target for treatment.

INTASYL is a promising, adaptable RNAi technology for treating skin cancers.

High-dose UVA-1 therapy improves symptoms and skin condition in sclerosing skin disease.

Predstanormix Duo is a safe and effective new drug for treating urinary symptoms from BPH.

A potential treatment for atopic dermatitis could be to increase PADI1 expression to improve skin barrier function.

Blocking IL-12 can help treat alopecia areata by preventing hair follicle immune issues.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Tph cells are linked to the severity of systemic lupus erythematosus.

An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.

JAK inhibitors show promise for treating various skin diseases.

Rituximab treatment led to complete hair regrowth and improved skin in a woman with pemphigus foliaceus.

Panitumumab treatment can cause unusual hair growth in some colorectal cancer patients.

Abrocitinib at 100 mg and 200 mg daily may significantly improve moderate-to-severe atopic dermatitis in patients 12 years and older.

Amivantamab can cause severe skin eruptions and scarring, requiring drug discontinuation and early treatment.

Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.